Abatacept in combination with ATLG reduces acute GvHD incidence and improves outcomes of children transplanted from mismatched unrelated donors: a real-world, multicenter, retrospective study.

methotrexate - Generic mfg.

Orencia (abatacept) - BMS

Abatacept in combination with ATLG reduces acute GvHD incidence and improves outcomes of children transplanted from mismatched unrelated donors: a real-world, multicenter, retrospective study. (PubMed, Transplant Cell Ther) - Oct 10, 2026 - "Our data indicate that in patients undergoing mismatched HSCT, ABA, added to a standard GvHD prophylaxis, is a suitable option for preventing GvHD, without impairing the graft-versus-leukemia effect."
Journal • Real-world evidence • Retrospective data • Acute Graft versus Host Disease • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Oncology • Pediatrics • Transplantation

http://www.ncbi.nlm.nih.gov/pubmed/42855012

Daria Pagliara; Emilia Boccieri; Franca Fagioli; Francesco Quagliarella; Franco Locatelli; Giovanna Lucchini; Ingvild Heier; Jochen Buechner; Manuela Tumino; Marco Andreani; Marco Becilli; Marco Zecca; Maria Ester Bernardo; Maria Giuseppina Cefalo; Matteo Becci; Mattia Algeri; Maura Faraci; Pietro Merli; Riccardo Masetti; Salvatore Perdichizzi

Oct 10, 2026